Toll Free: 1-888-928-9744

Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016

Published: May 31, 2016 | Pages: 2277 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Non-Hodgkin Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Hodgkin Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9 Top Five Countries Contributing to Clinical Trials in Europe 10 Top Countries Contributing to Clinical Trials in North America 11 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12 Top Five Countries Contributing to Clinical Trials in Central and South America 13 Clinical Trials by G7 Countries: Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials 14 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials 17 Clinical Trials by Phase in E7 Countries 18 Clinical Trials in E7 Countries by Trial Status 19 Clinical Trials by Phase 20 In Progress Trials by Phase 21 Clinical Trials by Trial Status 22 Clinical Trials by End Point Status 23 Subjects Recruited Over a Period of Time 24 Clinical Trials by Sponsor Type 25 Prominent Sponsors 26 Top Companies Participating in Non-Hodgkin Lymphoma Therapeutics Clinical Trials 27 Prominent Drugs 28 Latest Clinical Trials News on Non-Hodgkin Lymphoma 29 May 12, 2016: Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology 29 Apr 28, 2016: Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 29 Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016 30 Apr 19, 2016: Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting 31 Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016 32 Apr 18, 2016: Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016 33 Apr 18, 2016: Seattle Genetics Highlights Data on ADCETRIS at the American Association for Cancer Research Annual Meeting 33 Apr 18, 2016: TG Therapeutics Announces Pre-Clinical Data Presentation on TGR-1202 Demonstrating Differentiated Effects on T-Cells 34 Mar 18, 2016: Asana BioSciences, to Provide Update on ASN003, a Novel BRAF/PI3K Kinase Inhibitor, at the 14th International Congress on Targeted Anticancer Therapies 34 Mar 17, 2016: Epizyme to Present New Data in Support of Tazemetostat Clinical Development Program 35 Mar 17, 2016: TG Therapeutics Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research Annual Meeting 35 Mar 16, 2016: Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research 36 Mar 09, 2016: Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen 36 Clinical Trial Profile Snapshots 38 Appendix 2274 Abbreviations 2274 Definitions 2274 Research Methodology 2275 Secondary Research 2275 About GlobalData 2276 Contact Us 2276 Disclaimer 2276 Source 2277
List of Tables
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Region, 2016* 6 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13 Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14 Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17 Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2016* 20 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Non-Hodgkin Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28


List of Figures
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13 Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14 Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17 Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21 Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Non-Hodgkin Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28 GlobalData Methodology 2275

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify